Brittney DeClerck
Featured in:
Articles
-
1 month ago |
onlinelibrary.wiley.com | Stephanie Wang |Joanne Xiu |Katherine Butcher |Brittney DeClerck
Acral lentiginous melanoma (ALM) responds poorly to anti-PD1 therapy alone and in combination with anti-CTLA4 and lacks reliable targets for molecularly guided therapy, underscoring the need for novel therapeutic approaches in this rare melanoma subtype.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →